Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI

Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI

The recent first global approval of delafloxacin has been reviewed in detail in the First Global Approval report in Adis journal Drugs[1], based on the development milestones tracked in AdisInsight.[2] Continue reading “Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI”

New health economics book gets airtime

New health economics book gets airtime

Professor Simon Eckermann recently launched his book Health Economics from Theory to Practice: Optimally Informing Joint Decisions of Research, Reimbursement and Regulation with Health System Budget Constraints and Community Objectives. Now, a related interview with Professor Eckermann has been broadcast on National Radio’s Health Report. This reflects the fact that, although it is a high-level academic book aimed at specialist audiences, the application of health economics is relevant to the general population. The book provides a robust set of health economic principles and methods to inform societal decisions in relation to research, reimbursement and regulation (pricing and monitoring of performance in practice). The recent launch of the book involved a public policy lecture entitled “Successful baby boomer ageing with budget constraints: where should baby boomer ageing be heading”.

Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer

Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease;  immune-stimulation brings hope in bladder cancer

The recent first global approval of durvalumab has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1] based on the development milestones tracked in AdisInsight.[2] Continue reading “Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer”

Abaloparatide (Tymlos™): First Global Approval – bone formation fends off fragility fractures in postmenopausal women with high-risk osteoporosis

Abaloparatide (Tymlos™): First Global Approval – bone formation fends off fragility fractures in postmenopausal women with high-risk osteoporosis

The recent first global approval of abaloparatide has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Abaloparatide (Tymlos™): First Global Approval – bone formation fends off fragility fractures in postmenopausal women with high-risk osteoporosis”